A. Martín

发表

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.

E. Assenat, S. Paik, T. Decaens, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.

E. Assenat, S. Paik, M. Shimada, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.